INSPHERO: 3D CELL-BASED SOLUTIONS FOR DRUG DISCOVERY ANDSCIENCEAPPLICATIONSPRODUCTSSERVICESABOUTSUPPORT With our partners in academia and industry, we advance drug discovery and understanding of healthy and diseased human biology using an inspired combination of bioengineering, microtechnologies, and computational approaches to better predict the patient response in

vitro.

INSPHERO

InSphero sets the global gold standard for advanced, yet easy-to-use 3D tissue-based assay solutions for predictive compound classification. Our customers in the pharmaceutical, biotech, cosmetics and chemical/environmental industries rely on our robust, convenient and internationally recognized solutions to make informed

decisions during

3D INSIGHT™ LIVER MICROTISSUES, 3D LIVER MODELS InSphero platforms for liver disease and toxicology include everything you need to quickly integrate reliable, functionally robust 3D spheroid models into your drug R&D workflow. Our organotypic 3D liver models are the gold standard for more predictive, physiologically AKURA™ FLOW MICROPHYSIOLOGICAL DISCOVERY PLATFORM InSphero's Akura™ Flow microphysiological system is based on our unique organ-on-a-chip technology that makes microfluidics accessible to bench scientists & offers plug-and-play flexibility to design MPS systems using our models for metabolic disease and oncology research. INSPHERO AND HAMILTON ANNOUNCE COLLABORATION TO IMPROVE InSphero and Hamilton Announce Collaboration to Improve the Production and Handling of Spheroids Using Advanced Liquid Handling Technology. Both partners have a proven track record for being a successful entrepreneur and a technical disruptor at the intersection of INSPHERO AND ERASMUS MEDICAL CENTER CANCER RESEARCHER InSphero and Erasmus Medical Center Cancer Researcher Receive Grant to Develop Human In Vitro Model of Metastasis using the Akura™ Flow Technology Platform PDF version Schlieren, Switzerland – INSPHERO INTRODUCES REVOLUTIONARY NEW TRANSPORT TECHNOLOGY InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company has completely reengineered its live microtissue shipping technology and is introducing InFloat™: a unique shipping system designed to keep plates of assay-ready 3D InSight™ microtissues upright, secure, and at physiological temperatures suitable for live cell cultures during domestic and INSPHERO INFLOAT™ MICROTISSUE SHIPPING SYSTEM WINS COVETED InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company has won the prestigious Red Dot Best of the Best award for product design in the category of industrial equipment, and automation for its InFloat™ Shipping Technology. The InFloat™ shipping system ensures that plates of assay-ready 3D InSight™ microtissues not only remain upright, but also 3D INSIGHT™ HUMAN LIVER MICROTISSUES (AKURA™ 96 PLATE Complete turnkey solutions offers lower cost-of-ownership than in-house production. Technical specifications. PHH from pooled male/female donors. Co-culture with Kupffer cells and LECs. Guaranteed 28 days viability. 96-well format, 1 microtissue per well. Delivered with min. 50 mL of 3D InSight™ Liver Maintenance Medium. Biweekly

production.

IRINA AGARKOVA, NICOLE BUSCHMANN, FRANCESCA CHIOVARO Irina Agarkova, Nicole Buschmann, Francesca Chiovaro, Tamara Tanos, Sumeer Dhar, Wolfgang Moritz, Simon Messner, Jens Kelm, Patrick Guye InSphero AG, Wagistrasse 27 INSPHERO: 3D CELL-BASED SOLUTIONS FOR DRUG DISCOVERY ANDSCIENCEAPPLICATIONSPRODUCTSSERVICESABOUTSUPPORT With our partners in academia and industry, we advance drug discovery and understanding of healthy and diseased human biology using an inspired combination of bioengineering, microtechnologies, and computational approaches to better predict the patient response in

vitro.

INSPHERO

InSphero sets the global gold standard for advanced, yet easy-to-use 3D tissue-based assay solutions for predictive compound classification. Our customers in the pharmaceutical, biotech, cosmetics and chemical/environmental industries rely on our robust, convenient and internationally recognized solutions to make informed

decisions during

3D INSIGHT™ LIVER MICROTISSUES, 3D LIVER MODELS InSphero platforms for liver disease and toxicology include everything you need to quickly integrate reliable, functionally robust 3D spheroid models into your drug R&D workflow. Our organotypic 3D liver models are the gold standard for more predictive, physiologically AKURA™ FLOW MICROPHYSIOLOGICAL DISCOVERY PLATFORM InSphero's Akura™ Flow microphysiological system is based on our unique organ-on-a-chip technology that makes microfluidics accessible to bench scientists & offers plug-and-play flexibility to design MPS systems using our models for metabolic disease and oncology research. INSPHERO AND HAMILTON ANNOUNCE COLLABORATION TO IMPROVE InSphero and Hamilton Announce Collaboration to Improve the Production and Handling of Spheroids Using Advanced Liquid Handling Technology. Both partners have a proven track record for being a successful entrepreneur and a technical disruptor at the intersection of INSPHERO AND ERASMUS MEDICAL CENTER CANCER RESEARCHER InSphero and Erasmus Medical Center Cancer Researcher Receive Grant to Develop Human In Vitro Model of Metastasis using the Akura™ Flow Technology Platform PDF version Schlieren, Switzerland – INSPHERO INTRODUCES REVOLUTIONARY NEW TRANSPORT TECHNOLOGY InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company has completely reengineered its live microtissue shipping technology and is introducing InFloat™: a unique shipping system designed to keep plates of assay-ready 3D InSight™ microtissues upright, secure, and at physiological temperatures suitable for live cell cultures during domestic and INSPHERO INFLOAT™ MICROTISSUE SHIPPING SYSTEM WINS COVETED InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company has won the prestigious Red Dot Best of the Best award for product design in the category of industrial equipment, and automation for its InFloat™ Shipping Technology. The InFloat™ shipping system ensures that plates of assay-ready 3D InSight™ microtissues not only remain upright, but also 3D INSIGHT™ HUMAN LIVER MICROTISSUES (AKURA™ 96 PLATE Complete turnkey solutions offers lower cost-of-ownership than in-house production. Technical specifications. PHH from pooled male/female donors. Co-culture with Kupffer cells and LECs. Guaranteed 28 days viability. 96-well format, 1 microtissue per well. Delivered with min. 50 mL of 3D InSight™ Liver Maintenance Medium. Biweekly

production.

IRINA AGARKOVA, NICOLE BUSCHMANN, FRANCESCA CHIOVARO Irina Agarkova, Nicole Buschmann, Francesca Chiovaro, Tamara Tanos, Sumeer Dhar, Wolfgang Moritz, Simon Messner, Jens Kelm, Patrick Guye InSphero AG, Wagistrasse 27

PRODUCTS | INSPHERO

InSphero assay-ready spheroid microtissues are engineered and certified for use in critical drug development applications, and validated to ensure uniform

ABOUT | INSPHERO

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of 3D InSight™ Platforms and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. 3D INSIGHT™ LIVER MICROTISSUES, 3D LIVER MODELS InSphero platforms for liver disease and toxicology include everything you need to quickly integrate reliable, functionally robust 3D spheroid models into your drug R&D workflow. Our organotypic 3D liver models are the gold standard for more predictive, physiologically 3D INSIGHT™ HUMAN ISLET MICROTISSUES, HUMAN ISLET MODEL Production of 3D InSight™ Islet Microtissues starts with fine-tuned dissociation of primary donor islets, followed by controlled scaffold-free cellular reassembly and maturation in customized media that support maximum survival and optimal metabolic functionality of highly sensitive primary islet cells.The resulting uniform islets provide minimal intra-assay and intra-donor variability AKURA™ FLOW MICROPHYSIOLOGICAL DISCOVERY PLATFORM InSphero's Akura™ Flow microphysiological system is based on our unique organ-on-a-chip technology that makes microfluidics accessible to bench scientists & offers plug-and-play flexibility to design MPS systems using our models for metabolic disease and oncology research.

SPHEROIDS-HOME

Phone : +1-800-779-7558 (USA and Canada) Phone : +41 44 515 04 90 (Europe and Rest of World) Contact Us 3D INSIGHT™ MICROTISSUES FORMATS The scalable Akura™ 3D cell technology underlying InSphero's 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.

PRODUCTION SCHEDULE

3D InSight™ Human Liver Toxicology Models Production lead time: 1 week Catalog # Description MT-02-302-04 3D InSight™ Human Liver Microtissues (multi-donor hepatocytes, co-culture with Kupffer cells and liver endothelial cells), 96x Order by Ships on: US Ships MARION BAVAND, PHD, MBA A seasoned Quality Assurance and Regulatory Affairs professional with 20+ years of experience in pre-market and post-market product development of life science & biotech products and medical devices, including medical device vigilance and post-market surveillance.

JUNE 13, 2018

InSphero Receives Additional USD 10m for Organ-on-a-Chip Disease Models. Comprehensive, customizable platforms for preclinical drug safety and efficacy testing, coupled with emerging organ-on-a-chip technology, garner investor support. INSPHERO: 3D CELL-BASED SOLUTIONS FOR DRUG DISCOVERY ANDSCIENCEAPPLICATIONSPRODUCTSSERVICESABOUTSUPPORT With our partners in academia and industry, we advance drug discovery and understanding of healthy and diseased human biology using an inspired combination of bioengineering, microtechnologies, and computational approaches to better predict the patient response in

vitro.

INSPHERO

InSphero sets the global gold standard for advanced, yet easy-to-use 3D tissue-based assay solutions for predictive compound classification. Our customers in the pharmaceutical, biotech, cosmetics and chemical/environmental industries rely on our robust, convenient and internationally recognized solutions to make informed

decisions during

AKURA™ FLOW MICROPHYSIOLOGICAL DISCOVERY PLATFORM InSphero's Akura™ Flow microphysiological system is based on our unique organ-on-a-chip technology that makes microfluidics accessible to bench scientists & offers plug-and-play flexibility to design MPS systems using our models for metabolic disease and oncology research.

SPHEROIDS-HOME

Phone : +1-800-779-7558 (USA and Canada) Phone : +41 44 515 04 90 (Europe and Rest of World) Contact Us INSPHERO AND HAMILTON ANNOUNCE COLLABORATION TO IMPROVE InSphero and Hamilton Announce Collaboration to Improve the Production and Handling of Spheroids Using Advanced Liquid Handling Technology. Both partners have a proven track record for being a successful entrepreneur and a technical disruptor at the intersection of INSPHERO INFLOAT™ MICROTISSUE SHIPPING SYSTEM WINS COVETED InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company has won the prestigious Red Dot Best of the Best award for product design in the category of industrial equipment, and automation for its InFloat™ Shipping Technology. The InFloat™ shipping system ensures that plates of assay-ready 3D InSight™ microtissues not only remain upright, but also INSPHERO AND ERASMUS MEDICAL CENTER CANCER RESEARCHER InSphero and Erasmus Medical Center Cancer Researcher Receive Grant to Develop Human In Vitro Model of Metastasis using the Akura™ Flow Technology Platform PDF version Schlieren, Switzerland – 3D INSIGHT™ HUMAN LIVER MICROTISSUES (AKURA™ 96 PLATE Complete turnkey solutions offers lower cost-of-ownership than in-house production. Technical specifications. PHH from pooled male/female donors. Co-culture with Kupffer cells and LECs. Guaranteed 28 days viability. 96-well format, 1 microtissue per well. Delivered with min. 50 mL of 3D InSight™ Liver Maintenance Medium. Biweekly

production.

MARION BAVAND, PHD, MBA A seasoned Quality Assurance and Regulatory Affairs professional with 20+ years of experience in pre-market and post-market product development of life science & biotech products and medical devices, including medical device vigilance and post-market surveillance. IRINA AGARKOVA, NICOLE BUSCHMANN, FRANCESCA CHIOVARO Irina Agarkova, Nicole Buschmann, Francesca Chiovaro, Tamara Tanos, Sumeer Dhar, Wolfgang Moritz, Simon Messner, Jens Kelm, Patrick Guye InSphero AG, Wagistrasse 27 INSPHERO: 3D CELL-BASED SOLUTIONS FOR DRUG DISCOVERY ANDSCIENCEAPPLICATIONSPRODUCTSSERVICESABOUTSUPPORT With our partners in academia and industry, we advance drug discovery and understanding of healthy and diseased human biology using an inspired combination of bioengineering, microtechnologies, and computational approaches to better predict the patient response in

vitro.

INSPHERO

InSphero sets the global gold standard for advanced, yet easy-to-use 3D tissue-based assay solutions for predictive compound classification. Our customers in the pharmaceutical, biotech, cosmetics and chemical/environmental industries rely on our robust, convenient and internationally recognized solutions to make informed

decisions during

AKURA™ FLOW MICROPHYSIOLOGICAL DISCOVERY PLATFORM InSphero's Akura™ Flow microphysiological system is based on our unique organ-on-a-chip technology that makes microfluidics accessible to bench scientists & offers plug-and-play flexibility to design MPS systems using our models for metabolic disease and oncology research.

SPHEROIDS-HOME

Phone : +1-800-779-7558 (USA and Canada) Phone : +41 44 515 04 90 (Europe and Rest of World) Contact Us INSPHERO AND HAMILTON ANNOUNCE COLLABORATION TO IMPROVE InSphero and Hamilton Announce Collaboration to Improve the Production and Handling of Spheroids Using Advanced Liquid Handling Technology. Both partners have a proven track record for being a successful entrepreneur and a technical disruptor at the intersection of INSPHERO INFLOAT™ MICROTISSUE SHIPPING SYSTEM WINS COVETED InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company has won the prestigious Red Dot Best of the Best award for product design in the category of industrial equipment, and automation for its InFloat™ Shipping Technology. The InFloat™ shipping system ensures that plates of assay-ready 3D InSight™ microtissues not only remain upright, but also INSPHERO AND ERASMUS MEDICAL CENTER CANCER RESEARCHER InSphero and Erasmus Medical Center Cancer Researcher Receive Grant to Develop Human In Vitro Model of Metastasis using the Akura™ Flow Technology Platform PDF version Schlieren, Switzerland – 3D INSIGHT™ HUMAN LIVER MICROTISSUES (AKURA™ 96 PLATE Complete turnkey solutions offers lower cost-of-ownership than in-house production. Technical specifications. PHH from pooled male/female donors. Co-culture with Kupffer cells and LECs. Guaranteed 28 days viability. 96-well format, 1 microtissue per well. Delivered with min. 50 mL of 3D InSight™ Liver Maintenance Medium. Biweekly

production.

MARION BAVAND, PHD, MBA A seasoned Quality Assurance and Regulatory Affairs professional with 20+ years of experience in pre-market and post-market product development of life science & biotech products and medical devices, including medical device vigilance and post-market surveillance. IRINA AGARKOVA, NICOLE BUSCHMANN, FRANCESCA CHIOVARO Irina Agarkova, Nicole Buschmann, Francesca Chiovaro, Tamara Tanos, Sumeer Dhar, Wolfgang Moritz, Simon Messner, Jens Kelm, Patrick Guye InSphero AG, Wagistrasse 27

INSPHERO SCIENCE

Our technology enables life science companies to invent novel compounds in a safer, more efficient, faster, & animal-free way. InSphero's assay-ready 3D microtissues & solutions help pharmaceutical, cosmetics & chemical companies accelerate safety & efficacy testing, & bring better drugs to market.

ABOUT | INSPHERO

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of 3D InSight™ Platforms and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. SCIENTIFIC PUBLICATIONS & PRESENTATIONS Read InSphero's publications and view presentations about our liver, islet, cardiac & stem-cell derived microtissues, as well as scaffold-free 3D technologies, body on a chip, and more. 3D INSIGHT™ LIVER MICROTISSUES, 3D LIVER MODELS InSphero platforms for liver disease and toxicology include everything you need to quickly integrate reliable, functionally robust 3D spheroid models into your drug R&D workflow. Our organotypic 3D liver models are the gold standard for more predictive, physiologically

SPHEROIDS-HOME

Phone : +1-800-779-7558 (USA and Canada) Phone : +41 44 515 04 90 (Europe and Rest of World) Contact Us

CAREERS | INSPHERO

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our physiologically relevant suite of 3D InSight™ Microtissues and Services increase efficiency in drug discovery and safety testing. INSPHERO AND HAMILTON ANNOUNCE COLLABORATION TO IMPROVE InSphero and Hamilton Announce Collaboration to Improve the Production and Handling of Spheroids Using Advanced Liquid Handling Technology. Both partners have a proven track record for being a successful entrepreneur and a technical disruptor at the intersection of

DISEASE MODELS

3D InSight™ Human Liver Disease Models are based on 3D InSight™ Human Liver Microtissue technology and include specially formulated media and cocktails to induce the desired disease state in healthy

liver microtissues.

CONTACT US | INSPHERO InSphero Inc., TechPlace, 74 Orion St., Brunswick, ME 04011 USA +1 800-779-7558 +1-207-613-1489. Technical Support | Partnership &

Platform Inquiries

JUNE 13, 2018

InSphero Receives Additional USD 10m for Organ-on-a-Chip Disease Models. Comprehensive, customizable platforms for preclinical drug safety and efficacy testing, coupled with emerging organ-on-a-chip technology, garner investor support. InSphero: 3D Cell-Based Solutions for Drug Discovery and Safety

Testing

News

* Register for our free educational webinars on innovative 3D cell technologies for drug discovery and safety testing. Read more >> * InSphero labs are fully operational and we are accepting new liver tox, NASH, and diabetes projects.   Read More >> * InSphero offers Academic Access Program for research groups eager to apply Akura™ Flow organ-on-chip technology. Read more >> * InSphero launches online store to streamline ordering process for researchers heading back the bench as COVID-19 shutdown ends. Read

more >>

* SCIENCE

* Why InSphero?

* Enabling Technology * 3D Select™ Process * Microtissue Formats * Organ-on-a-chip Systems * Live Microtissue Shipping

* Publications

* Peer-reviewed Papers

* White Papers

* Posters

* Blog

* Digital Media

* Videos

* Webinars

* Seminars

* APPLICATIONS

* Application Overview

* Liver Toxicology

* DILI Prediction

* Mechanistic Assays

* Metabolic Disease

* Diabetes & Islet Research

* Liver Disease

* Oncology

* Efficacy Testing

* Immuno-oncology

* PRODUCTS

* 3D InSight™ Platforms

* Liver

* Liver Disease

* Steatosis

* NASH

* Liver Toxicology

* Human

* Animal

* Islet

* Human

* Rat

* Platform Add-Ons

* Tumor

* Assay-ready Models

* PDX Models

* Custom Model Development

* How to Order

* SERVICES

* Services Overview

* _In Vitro_ Toxicology * 14 Day Hepatotoxicity * Custom Mechanistic and Investigative Studies * Pancreatic Endocrine Toxicity * Diabetes and NASH Drug Discovery * Diabetes Drug Testing

* NASH Drug Testing

* Oncology Drug Discovery * Custom Tumor Model Development

* Efficacy Testing

* Combinatorial Drug Testing * Tumor Relapse Assay * Antibody Penetration

* Immuno-Oncology

* How to Get Started

* ABOUT

* About InSphero

* Leadership

* Careers

* Contact Us

* Our Partners

* News & Events

* Newsletter

* Media Releases

* Fairs, Conferences & Events

* SUPPORT

* Help Center

* Production Schedule * Protocols and Manuals

* Customer Portal

* BLOG

* __

__

__ __

__

Innovate

Investigate

Discover

TOGETHER

Together with our partners in academia and industry, InSphero advances drug discovery and our understanding of healthy and diseased human biology using an inspired combination of bioengineering, microtechnologies, and computational approaches. Discover how we can help propel your programs forward.

Join Us!

GET STARTED WITH INSPHERO Learn how InSphero can propel your drug discovery and safety testing programs forward! Help us better understand your challenges and interests, and let's get started!

* First Name*

* Last Name*

* Company/Institution*

* Email*

* Phone Number

* Country*

United StatesCanadaAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAntigua and BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia and HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCape VerdeCayman IslandsCentral African RepublicChadChileChinaColombiaComorosCongo, Democratic Republic of theCongo, Republic of theCosta RicaCôte d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEast TimorEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGreenlandGrenadaGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiNorth

KoreaSouth

KoreaKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew ZealandNicaraguaNigerNigeriaNorwayNorthern Mariana IslandsOmanPakistanPalauPalestinePanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaSaint Kitts and NevisSaint LuciaSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbia and MontenegroSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSpainSri LankaSudanSudan, SouthSurinameSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamVirgin Islands, BritishVirgin Islands, U.S.YemenZambiaZimbabwe

* State/Prov

AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict

of

ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed

Forces Pacific

* State/Prov

AlbertaBritish ColumbiaManitobaNew BrunswickNewfoundland & LabradorNorthwest TerritoriesNova ScotiaNunavutOntarioPrince Edward IslandQuebecSaskatchewanYukon

* State/Prov

* Applications of Interest * Toxicity and safety testing

* Cancer research

* Type II diabetes and obesity research

* Type 1 diabetes

* Liver disease (e.g. NAFLD, NASH)

* Cosmetics testing

* Organs-on-chips/Microfluidics * Assay-ready models of interest * Human Liver Microtissues * Human Islet Microtissues * Monkey Liver Microtissues * Rat Islet Microtissues * Dog Liver Microtissues * Tumor/Stromal Co-cultures * Rat Liver Microtissues * Custom Tumor Model Development * Platforms and services of interest

* Liver Toxicology

* Diabetes Discovery * NAFLD & NASH Discovery * Oncology Discovery * What 3D challenge can we help you solve today?

* CAPTCHA

* Name

This field is for validation purposes and should be left unchanged. GAIN UNRIVALED BIOLOGICAL INSIGHT

LIVER DISEASE

Investigate Together Screen and test efficacy of NAFLD and NASH drugs with a platform that mimics the disease progression in patients.

Learn More

DIABETES

_DISCOVER TOGETHER_

Conduct type 1 & type 2 diabetes research in a platform that ensures uniform, long-lived islets with robust functionality.

Learn More

ONCOLOGY

_INNOVATE TOGETHER_

Reflect complex 3D tumor microenvironments with tumor, stromal, and

immune components.

Learn More

TOXICOLOGY

Advance Together

Predict drug-induced liver injury with twice the sensitivity without sacrificing specificity in 3D human liver toxicology models.

Learn More

Our 3D InSight™ platforms include everything you need to optimize your investment in 3D _in vitro_ cell technology: physiologically relevant microtissue models, specially formulated media, 3D assay protocols, and expert support from experienced application scientists. Whether you want to leverage our innovative assay-ready 3D technology in-house or partner with us on longer-term collaborative research projects to investigate complex diseases, we can propel your drug discovery and safety testing programs forward. POWERED BY SCALABLE AKURA™ 3D CELL CULTURE TECHNOLOGY Watch how we apply our scalable technology and organ-on-a-chip solutions to engineer powerful and flexible 3D _in vitro_ platforms for drug efficacy and safety testing and the study of metabolic disease

and

cancers .

FOR BETTER, SAFER DRUGS. FASTER.

.

WHY PARTNER WITH INSPHERO? Add the pioneer in 3D cell-based assay solutions and scaffold-free organ-on-a-chip technology to your drug R&D team and see immediate

results.

RELEVANT

Work with 3D platforms precisely engineered to mimic human biology and save you years of model development and assay testing time.

RELIABLE

Rely on functionally robust, highly standardized microtissue models and 3D-optimized experimental programs. InSphero is ISO 9001:2015

certified

and committed to your success.

REPRODUCIBLE

Ensure reproducible data and minimize confounding factors — regardless of the scale and complexity of your experimental programs. _“Addressing complex diseases requires the rare combination of pioneering innovation and biomedical expertise. As our discovery partner, InSphero gives us immediate access to new technologies, such as organ-on-a-chip systems, that provide deep mechanistic insights into complex diseases. They have become part of our research team, committed to helping us find a cure for type 1 diabetes.”_ MATTHIAS VON HERRATH, MD _Professor and Director of the Center for Type 1 Diabetes Research La Jolla Institute of Immunology_ _Vice President and Senior Medical Officer

Novo Nordisk_

FIND OUT HOW INSPHERO 3D INSIGHT™ PLATFORMS AND AKURA™ TECHNOLOGY CAN HELP DRIVE EFFICIENT INNOVATION IN DRUG R&D FOR YOUR ORGANIZATION.

Get Started

GET STARTED WITH INSPHERO Learn how InSphero can propel your drug discovery and safety testing programs forward! Help us better understand your challenges and interests, and let's get started!

* First Name*

* Last Name*

* Company/Institution*

* Email*

* Phone Number

* Country*

United StatesCanadaAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAntigua and BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia and HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCape VerdeCayman IslandsCentral African RepublicChadChileChinaColombiaComorosCongo, Democratic Republic of theCongo, Republic of theCosta RicaCôte d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEast TimorEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGreenlandGrenadaGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiNorth

KoreaSouth

KoreaKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew ZealandNicaraguaNigerNigeriaNorwayNorthern Mariana IslandsOmanPakistanPalauPalestinePanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaSaint Kitts and NevisSaint LuciaSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbia and MontenegroSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSpainSri LankaSudanSudan, SouthSurinameSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamVirgin Islands, BritishVirgin Islands, U.S.YemenZambiaZimbabwe

* State/Prov

AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict

of

ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed

Forces Pacific

* State/Prov

AlbertaBritish ColumbiaManitobaNew BrunswickNewfoundland & LabradorNorthwest TerritoriesNova ScotiaNunavutOntarioPrince Edward IslandQuebecSaskatchewanYukon

* State/Prov

* Applications of Interest * Toxicity and safety testing

* Cancer research

* Type II diabetes and obesity research

* Type 1 diabetes

* Liver disease (e.g. NAFLD, NASH)

* Cosmetics testing

* Organs-on-chips/Microfluidics * Assay-ready models of interest * Human Liver Microtissues * Human Islet Microtissues * Monkey Liver Microtissues * Rat Islet Microtissues * Dog Liver Microtissues * Tumor/Stromal Co-cultures * Rat Liver Microtissues * Custom Tumor Model Development * Platforms and services of interest

* Liver Toxicology

* Diabetes Discovery * NAFLD & NASH Discovery * Oncology Discovery * What 3D challenge can we help you solve today?

* CAPTCHA

* Email

This field is for validation purposes and should be left unchanged. Phone : +1-800-779-7558

(USA and Canada)

Phone : +41 44 515 04 90 (Europe and Rest of World)

Contact Us

SCIENCE

* Why InSphero?

* Enabling Technology

* Publications

* Blog

* Videos and Webinars

APPLICATIONS

* Application Overview

* Liver Toxicology

* Metabolic Disease

* Oncology

PRODUCTS

* 3D InSight™ Platforms

* Liver

* Islet

* Tumor

* How to Order

SERVICES

* Services Overview

* _In Vitro_ Toxicology * Metabolic Disease Discovery * Oncology Drug Discovery * How to Get Started

ABOUT

* About InSphero

* Leadership

* Careers

* Contact Us

* Our Partners

* News & Events

SUPPORT

* Help Center

* Production Schedule * Protocols and Manuals

* Customer Portal

� InSphero. All rights reserved.  Privacy Policy |  Sitemap  |  Terms & Conditions

|  Imprint  |

Medical Disclaimer

Notifications